Monitoring of immune responses to CA125 with an IFN-γ ELISPOT assay

Journal of Immunological Methods

Volumn 279, Issue 1-2, 2003, Pages 1-15

  Schultes, Birgit C ^a   Whiteside, Theresa L ^b  

^a AltaRex Corp   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

CA125; Dendritic cells; ELISPOT; IFN ; Ovarian cancer; T cells

Indexed keywords

CA 125 ANTIGEN; GAMMA INTERFERON; OREGOVOMAB;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN DETECTION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL ASSAY; CELL IMMORTALIZATION; CELL SPECIFICITY; CELL TYPE; CONTROLLED STUDY; DENDRITIC CELL; DIAGNOSTIC VALUE; DRUG DETERMINATION; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL MONITORING; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MONONUCLEAR CELL; OVARY CANCER; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROLYMPHOCYTE; QUANTITATIVE ANALYSIS; SENSITIZATION; T LYMPHOCYTE; TITRIMETRY; VALIDATION PROCESS;

EID: 0142092650     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(03)00253-9     Document Type: Article

References (27)

1. Asai T., Storkus W.J., Whiteside T.L. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines. CDLI. 7:2000;145-154.
2. Bast C.R. Jr., Klug T.L., St. John E.et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309:1983;883.
3. Bennouna J., Hildesheim A., Chikamatsu K., Gooding W., Storkus W.J., Whiteside T.L. Application of IL-5 ELSIPOT assays to quantification of antigen-specific T helper responses. J. Immunol. Methods. 261:2002;145-156.
4. Berlyn K.A., Schultes B., Leveugle B., Noujaim A.A., Alexander R.B., Mann D.L. Generation of CD4+ and CD8+ lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen:antibody) complexes. Clin. Immunol. 101:2001;276-283.
5. Dhodapkar K.M., Krasovsky J., Williamson B., Dhodapkar M.V. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. 195:2002;125-133.
6. Ehlen T., Whiteside T.L., Schultes B.C., Siemens M., Noujaim A.A., Nicodemus C.F. Induction of tumor protective immunity utilizing the CA125 specific monoclonal, OvaRex® MAb-B43.13, in a cohort of patients with advanced recurrent ovarian cancer. Gynecol. Oncol. 80:2001;310.
7. Gordon A., Stringer A., Edwards R., Whiteside T., Fingert F., Schultes B. Clinical and immunologic outcomes of patients with recurrent epithelial ovarian cancer treated with OvaRex® MAb and chemotherapy. Gynecol. Oncol. 84:2002;501.
8. Herr W., Schneider J., Lohse A.W., Meyer zum Buschenfelde K.H., Wolfel T. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J. Immunol. Methods. 191:1996;131-143.
9. Hiltbold E.M., Vlad A.M., Ciborowski P., Watkins S.C., Finn O.J. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J. Immunol. 165:2000;3730-3741.
10. Hoffmann T.K.H., Meidenbauer N., Dworacki G., Kanaya H., Whiteside T.L. Generation of tumor-specific T lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res. 60:2000;3542-3549.
11. Hoffmann T.K., Meidenbauer N., Müller-Berghaus J., Storkus W.J., Whiteside T.L. Proinflammatory cytokines and CD40 ligand enhance cross-presentation and cross-priming capability of human dendritic cells internalizing apoptotic cancer cells. J. Immunother. 24:2001;162-171.
12. Jameson J., Gruz J., Ennis F.A. Human cytotoxic T-lymphocyte repertoire to influenza A virus. J. Virol. 72:1998;8682-8689.
13. Meidenbauer N., Harris D.T., Spitler L.E., Whiteside T.L. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate. 43:2000;88-100.
14. Method M.W., Gordon A., Finkler N., Fingert H., Nicodemus C., Schultes B., Whiteside T. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex® MAb B43.13 (OV) in Patients (Pts) with epithelial ovarian cancer (EOC). Proceedings of ASCO. 21:2002;21a.
15. Nicodemus C.F., Schultes B.C., Hamilton B.L. Immunomodulation with antibodies: clinical application in ovarian cancer and other malignancies. Expert Rev. Vaccines. 1:2002;35-48.
16. Noujaim A.A., Baum R.P., Sykes T.R.et al. Monoclonal antibody B43.13 for immunoscintigraphy and immunotherapy of ovarian cancer. Klapdor R. Current Tumor Diagnosis: Applications, Clinical Relevance, Trends. 1994;823-829 W. Zuckschwerdt Verlag, München.
17. Noujaim A.A., Schultes B.C., Baum R.P., Madiyalakan R. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13-evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. Cancer Biother. Radiopharm. 16:2001;187-203.
18. Nustad K., Bast R.C. Jr., Brien T.J.et al. Specificity and affinity of 26 monoclonal antibodies against the CA125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumor Biol. 17:1996;196.
19. Regnault D., Lankar V., Lacabanne A., Rodriguez C., Thery M., Rescigno T., Saito S., Verbeek C., Bonnerot P., Ricciardi-Castagnoli P., Amigorena S. Fcγ Receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189:1999;371-380.
20. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and down-regulated by tumor necrosis factor alpha. J. Exp. Med. 179:1994;1109-1118.
21. 1). Cancer Immunol. Immunother. 46:1998;201-212.
22. Schultes B.C., Gordon A., Ehlen T., Nicodemus C.F., Fingert H., Edwards R., Whiteside T.L. Induction of tumor- and CA125-specific T cell responses in patients with epithelial ovarian cancer treated with OvaRex® MAb-B43.13. Proc. Am. Assoc. Cancer Res. 43:2002;144.
23. Schultes B.C., Kuzma M.L., Agopsowicz K., Eng H., Nicodemus C.F., Noujaim A.A., Mann D.L. Antibodies as vaccines: immune complexes allow for efficient uptake and processing of antigens on MHC class I and II and induce maturation of dendritic cells. FASEB J. 246:2002;12.
24. Tosato G. Generation of EBV-immortalized B cell lines. Coico R. Current Protocols in Immunology. 1999;7.22.3 Wiley, New York.
25. Whiteside T.L. Monitoring of antigen-specific cytolytic T lymphocytes (CTL) in cancer patients treated with immunotherapy. CDLI. 7:2000;327-332.
26. Whiteside T.L., Hank J.A. Monitoring of immunologic therapies. Rose R.N., Hamilton R.G., Detrick B. Manual of Clinical Laboratory Immunology. 6th ed. 2002;1108-1117 ASM, Washington, DC.
27. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Gegnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M.N., Rubin S.C., Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348:2003;203-213.